Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
Harmony Biosciences reported Q1 revenue of $215.4 million, up 17% year-over-year, and reiterated full-year 2026 guidance of over $1 billion. The company confirmed its strategic pillars, including the protection of WAKIX IP into 2030 and the advancement of its pipeline with a Pitolisant GR NDA filing expected in Q2.
Key figures
- Eps
- 0.55
- Revenue
- 215400000
- Guidance
- 2026 WAKIX Net Revenue $1.0 billion - $1.04 billion
- Revenue Yoy
- 17%
- Rd expenses
- 69400000
- Operating income
- 37291000
- Cash and equivalents
- 870500000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.